News
Trial uses blood ctDNA to steer immunotherapy before colon cancer surgery
AI-assisted summary Written by WellCareChina with AI assistance and checked against the original article.
Fudan University Shanghai Cancer Center has registered a phase 2 study, first posted on 25 September 2026, that uses repeated blood tests for circulating tumour DNA (ctDNA) to guide immunotherapy given before surgery in patients with dMMR/MSI-H colon cancer. According to the record, participants whose ctDNA clears go on to surgery, while those whose ctDNA persists receive combined PD-1 and CTLA-4 inhibitor therapy. The single-arm study plans to enrol 23 participants; no results are posted yet.
Read the original article Opens the original source in a new tab.
Copyright and re-use
The original article is the authoritative text. This page carries our own summary and a link back; no part of the original is reproduced here.
Source tier A — trial registry record (public domain in the United States); our own summary and a link to the registry record, data as posted on 6 October 2026.